499 related articles for article (PubMed ID: 33180631)
1. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
2. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
[TBL] [Abstract][Full Text] [Related]
3. Identification of Biomarkers Based on Bioinformatics Analysis: The Expression of Ubiquitin-Conjugating Enzyme E2T (UBE2T) in the Carcinogenesis and Progression of Hepatocellular Carcinoma.
Zhao X; Weng W; Jin M; Li S; Chen Q; Li B; Zhou Z; Lan C; Yang Y
Med Sci Monit; 2021 Mar; 27():e929023. PubMed ID: 33658475
[TBL] [Abstract][Full Text] [Related]
4. UBE2T Contributes to the Prognosis of Esophageal Squamous Cell Carcinoma.
Wang X; Liu Y; Leng X; Cao K; Sun W; Zhu J; Ma J
Pathol Oncol Res; 2021; 27():632531. PubMed ID: 34257599
[No Abstract] [Full Text] [Related]
5. UBE2T is upregulated, predicts poor prognosis, and promotes cell proliferation and invasion by promoting epithelial-mesenchymal transition via inhibiting autophagy in an AKT/mTOR dependent manner in ovarian cancer.
Huang W; Huang H; Xiao Y; Wang L; Zhang T; Fang X; Xia X
Cell Cycle; 2022 Apr; 21(8):780-791. PubMed ID: 35130130
[TBL] [Abstract][Full Text] [Related]
6. Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis.
Zhang CY; Yang M
World J Hepatol; 2022 May; 14(5):956-971. PubMed ID: 35721293
[TBL] [Abstract][Full Text] [Related]
7. UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathway.
Hu W; Xiao L; Cao C; Hua S; Wu D
Oncotarget; 2016 Mar; 7(12):15161-72. PubMed ID: 26943030
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
9. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
10. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
Diao B; Yang P
Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer.
Tian X; Han Y; Yu L; Luo B; Hu Z; Li X; Yang Z; Wang X; Huang W; Wang H; Zhang Q; Ma D
Cancer Biol Ther; 2017 Apr; 18(4):245-251. PubMed ID: 28346042
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
15. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
16. UBE2C promotes the progression of head and neck squamous cell carcinoma.
Jin Z; Zhao X; Cui L; Xu X; Zhao Y; Younai F; Messadi D; Hu S
Biochem Biophys Res Commun; 2020 Mar; 523(2):389-397. PubMed ID: 31870550
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal cancer progression by facilitating ubiquitination and degradation of p53.
Wu M; Li X; Huang W; Chen Y; Wang B; Liu X
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101493. PubMed ID: 32736946
[TBL] [Abstract][Full Text] [Related]
18. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
[TBL] [Abstract][Full Text] [Related]
19. The expression of ubiquitin-conjugating enzyme E2C and KAI1 in ovarian carcinoma and their clinical significance.
Gong Y; Wang D; Lin L; Dai J; Yu L
Medicine (Baltimore); 2019 Nov; 98(46):e17896. PubMed ID: 31725636
[TBL] [Abstract][Full Text] [Related]
20. Inhibitor of DNA-binding family regulates the prognosis of ovarian cancer.
Zhou Q; Mei YD; Yang HJ; Tao YL
Future Oncol; 2021 May; 17(15):1889-1906. PubMed ID: 33728938
[No Abstract] [Full Text] [Related]
[Next] [New Search]
